In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Where’s The Comparative Effectiveness Money Going? Plan Is Due July 30

This article was originally published in The Gray Sheet

Executive Summary

Questions about how the economic stimulus package's $1.1 billion for comparative effectiveness research will be spent should be answered by July 30, when a report is due to Congress

You may also be interested in...



Advancing Comparative Effectiveness Research: An Interview with Sean Tunis

Sean Tunis is director of the Center for Medical Technology Policy and a leading advocate for comparative effectiveness research and evidence-based medicine. Formerly Director of the Office of Clinical Standards and Quality and CMO of the Centers for Medicare & Medicaid Services, he discusses the state of comparative effectiveness advocacy and his current work developing medical device protocols aimed at providing actionable information to physicians, patients, and payors.

Clancy Sees Future For Long-Term Comparative Effectiveness Research

A leading government proponent of evidence-based medicine is looking beyond stimulus funding that allocates hundreds of millions of dollars to comparative effectiveness research and is working to keep it viable for the long term

Clancy Sees Future For Long-Term Comparative Effectiveness Research

A leading government proponent of evidence-based medicine is looking beyond stimulus funding that allocates hundreds of millions of dollars to comparative effectiveness research and is working to keep it viable for the long term

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027146

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel